CLINICAL_TRIALS
trial_result
· 2015-08-17
Clinical Trial Update: A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma [Phase 2]
Summary
Phase 2 trial of JX-594 (Pexa-Vec), a recombinant vaccinia virus, for unresectable primary hepatocellular carcinoma has completed with results posted in 2015. T…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Jennerex Biotherapeutics | Conditions: Carcinoma, Hepatocellular | Phase 2 | Status: COMPLETED | Results posted: 2015-08-17